Massachusetts Sues Drug Executives Over Opioid Crisis
The suit, the first to target company executives, alleges that Purdue Pharma misled doctors and patients about risks and "peddled falsehoods" to sell more drugs and boost profits.BOSTON—Massachusetts is suing the maker of OxyContin over the deadly opioid crisis and is the first state to also target company executives.
Attorney General Maura Healey on Tuesday announced the lawsuit against Purdue Pharma and 16 current and former executives and board members, including CEO Craig Landau and members of the Sackler family, which owns the company.
The suit alleges Purdue misled doctors and patients about the risks of opioids and “peddled falsehoods” to sell more drugs and boost profits.
Healey says the Connecticut-based company’s “illegal business model” has left a “path of devastation and destruction.”
Several other states and localities have sued Purdue Pharma, but Healey says the Massachusetts lawsuit is the first to also name its executives.
Purdue Pharma told the Boston Globe it “vigorously” denies the allegations.
Rooted in Truth.Independent by Design.
Your support helps ensure that rigorous reporting, thoughtful analysis, and investigative journalism remain accessible to everyone.
Support independent journalism.
Courts & Law
This week's performative farce was the antithesis of justice. Even the factual numbers cited were lies or distortions.
Opinion
Though publicly shamed, the Sacklers avoided prison, remained billionaires, and are set to launch a new company, Knoa Pharma.
Immigration
Meet the deportation machine’s local partners.
Health & Wellness
Opioid overdose deaths are up in communities of color, even as they decrease overall.
Courts & Law
The chain is accused of pressuring pharmacists to fill as many prescriptions as they could and rewarding them for doing it fast — ‘like McDonalds.’
Opinion
Some members of the notorious Sackler family have returned to blaming doctors for the opioid crisis. Are they even wrong?
You need to be a supporter to comment.
There are currently no responses to this article.
Be the first to respond.